z-logo
open-access-imgOpen Access
Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation
Author(s) -
Jenny N. H. G. Ho,
Dominik Schmidt,
Theresa Lowinus,
Jeongmin Ryoo,
Elaine-Pashupati Dopfer,
Nicolás Gonzalo Núñez,
Sara Costa-Pereira,
Cristina Toffalori,
Marco Punta,
Viktor Fetsch,
Tobias Wertheimer,
Marie-Claire Rittmann,
Lukas M. Braun,
Marie Follo,
Christelle Briere,
Janaki Manoja Vinnakota,
Marlene Langenbach,
Felicitas Koppers,
Khalid Shoumariyeh,
Helena Engel,
Tamina Rückert,
Melanie Märklin,
Samuel Holzmayer,
Anna Lena Illert,
Federica Magon,
Geoffroy Andrieux,
Sandra Duquesne,
Dietmar Pfeifer,
Julian Staniek,
Marta Rizzi,
Cornelius Miething,
Natalie Köhler,
Justus Duyster,
Hans D. Menssen,
Melanie Boerries,
Joerg M. Buescher,
Nina CabezasWallscheid,
Bruce R. Blazar,
Petya Apostolova,
Luca Vago,
Erika L. Pearce,
Burkhard Becher,
Robert Zeiser
Publication year - 2022
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood.2022016082
Subject(s) - leukemia , myeloid leukemia , cancer research , cd8 , major histocompatibility complex , biology , immunology , mhc class i , transplantation , chemistry , immune system , medicine

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom